Bevacizumab not cost effective for HER2-negative mBC
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - March 1, 2017 Category: Drugs & Pharmacology Source Type: news

Vorinostat Plus Bevacizumab Had Activity in Previously Treated RCC
Using the HDAC inhibitor vorinostat plus the VEGF inhibitor bevacizumab resulted in clinical activity in patients with clear cell renal cell carcinoma. (Source: CancerNetwork)
Source: CancerNetwork - February 28, 2017 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Genitourinary Cancers News Renal Cell Carcinoma Source Type: news

First Look at Combo With Immunotherapy in Untreated mRCC First Look at Combo With Immunotherapy in Untreated mRCC
The immunotherapy atezolizumab in combination with bevacizumab had some'provocative'phase 2 results in untreated, advanced renal cell carcinoma.Medscape Medical News (Source: Medscape Radiology Headlines)
Source: Medscape Radiology Headlines - February 27, 2017 Category: Radiology Tags: Hematology-Oncology News Source Type: news

Why the CEO of ​Agenus says its cancer trial failure is no big deal
The CEO of Lexington drugmaker Agenus on Wednesday said the market's reaction to the failure of a mid-stage trial of a potential cancer drug was overblown, and doesn't mean the drug won't work in other trials. Agenus (Nasdaq: AGEN) disclosed in a federal filing Tuesday night that a Phase 2 trial of its Prophage vaccine in combination with Genentech’s cancer drug Avastin was likely futile. An interim analysis found that the survival rate of patients with brain tumors appeared no better than the… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - February 22, 2017 Category: Biotechnology Authors: Max Stendahl Source Type: news

Airbag-associated severe blunt eye injury causes choroidal rupture and retinal hemorrhage: a case report - Wang SH, Lim CC, Teng YT.
A case of choroidal rupture caused by airbag-associated blunt eye trauma and complicated with massive subretinal hemorrhage and vitreous hemorrhage that was successfully treated with intravitreal injection of expansile gas and bevacizumab is presented. A 5... (Source: SafetyLit)
Source: SafetyLit - February 22, 2017 Category: Global & Universal Tags: Engineering, Physics, Structural Soundness and Failure Source Type: news

Roche Says Phase II Trial Supports Twin Treatment for Kidney Cancer Roche Says Phase II Trial Supports Twin Treatment for Kidney Cancer
Swiss pharmaceuticals company Roche said on Saturday that a combination of its immunotherapy drug Tecentriq (atezolizumab) and its cancer drug Avastin (bevacizumab) had shown encouraging results in a Phase II trial in treating a type of kidney cancer.Reuters Health Information (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - February 21, 2017 Category: Allergy & Immunology Tags: Hematology-Oncology News Source Type: news

Negative Trial in Metastatic RCC Still Generates Buzz
(MedPage Today) -- Tecentriq-Avastin combo tops Sutent in PD-L1-positive group (Source: MedPage Today Urology)
Source: MedPage Today Urology - February 19, 2017 Category: Urology & Nephrology Source Type: news

Phase II study supports potential for Roche ’s TECENTRIQ (atezolizumab) plus Avastin (bevacizumab) for people with locally advanced or metastatic renal cell carcinoma
Roche today announced encouraging results from the Phase II IMmotion150 study that compared TECENTRIQ ® (atezolizumab) plus Avastin® (bevacizumab) and TECENTRIQ monotherapy to sunitinib alone in people with previously untreated, locally advanced or metastatic renal cell carcinoma (mRCC). (Source: Roche Media News)
Source: Roche Media News - February 18, 2017 Category: Pharmaceuticals Source Type: news

Phase II study supports potential for Roche ’s TECENTRIQ (atezolizumab) plus Avastin (bevacizumab) for people with locally advanced or metastatic renal cell carcinoma
Roche today announced encouraging results from the Phase II IMmotion150 study that compared TECENTRIQ ® (atezolizumab) plus Avastin® (bevacizumab) and TECENTRIQ monotherapy to sunitinib alone in people with previously untreated, locally advanced or metastatic renal cell carcinoma (mRCC). (Source: Roche Investor Update)
Source: Roche Investor Update - February 18, 2017 Category: Pharmaceuticals Source Type: news

Biotech giants square off in 'biosimilar' fight for top-selling cancer drug
Biotech titans Genentech Inc. and Amgen Inc. are going head-to-head over the $7 billion cancer-fighting drug Avastin. Genentech, the South San Francisco-based U.S. biotech unit of Swiss drug giant Roche, filed a suit Thursday in U.S. District Court in Delaware that could delay Amgen's lower-cost biosimilar version of Genentech's best-selling drug. It claims Amgen has obstructed it from evaluating ahead of a March 24 deadline whether any of its patents are infringed by Amgen's copy. If Genentech… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - February 17, 2017 Category: Biotechnology Authors: Ron Leuty Source Type: news

Biotech giants square off in 'biosimilar' fight for top-selling cancer drug
Biotech titans Genentech Inc. and Amgen Inc. are going head-to-head over the $7 billion cancer-fighting drug Avastin. Genentech, the South San Francisco-based U.S. biotech unit of Swiss drug giant Roche, filed a suit Thursday in U.S. District Court in Delaware that could delay Amgen's lower-cost biosimilar version of Genentech's best-selling drug. It claims Amgen has obstructed it from evaluating ahead of a March 24 deadline whether any of its patents are infringed by Amgen's copy. If Genentech… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - February 17, 2017 Category: American Health Authors: Ron Leuty Source Type: news

DelMar Pharma begins dosing in Phase II trial of VAL-083 to treat GBM
Biopharmaceutical firm DelMar Pharmaceuticals has begun dosing in a Phase II clinical trial of VAL-083 for the treatment of MGMT-unmethylated Avastin (bevacizumab)-na ï ve recurrent glioblastoma multiforme (GBM). (Source: Drug Development Technology)
Source: Drug Development Technology - February 14, 2017 Category: Pharmaceuticals Source Type: news

Roche denies rumors it will shop diabetes unit, earnings
Roche (PINK:RHHBY) denied rumors that it was considering selling its diabetes unit today, saying that it is “committed” to the business. The company also predicted that competition and spending on new drugs would stall its margin growth in 2017, as patents expire for its blockbuster medications. The Swiss drugmaker’s 3 top-selling cancer drugs, Rituxan, Herceptin and Avastin, bring in annual revenue of more than 20 billion Swiss francs, Reuters reported, and they face incoming competition from biosimilar copies. The 1st copies of Rituxan and Herceptin could hit the European market later thi...
Source: Mass Device - February 1, 2017 Category: Medical Equipment Authors: Sarah Faulkner Tags: Diabetes MassDevice Earnings Roundup Wall Street Beat Roche Roche Diabetes Care Source Type: news

Roche applied to take Avastin off WHO list due to safety issues
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - February 1, 2017 Category: Drugs & Pharmacology Source Type: news

Bevacizumab Combination Improves PFS, but Not OS, in Extensive-Disease SCLC
The addition of bevacizumab to a first-line regimen of cisplatin and etoposide improved progression-free survival in patients with extensive-disease small-cell lung cancer. (Source: CancerNetwork)
Source: CancerNetwork - January 30, 2017 Category: Cancer & Oncology Authors: Dave Levitan Tags: Lung Cancer News Source Type: news

CHARTA Shows Survival Benefit of Four-Drug Regimen for Advanced CRC
This video examines results of the CHARTA trial, which tested first-line FOLFOX plus bevacizumab with or without irinotecan in patients with advanced colorectal cancer. (Source: CancerNetwork)
Source: CancerNetwork - January 22, 2017 Category: Cancer & Oncology Authors: Hans-Joachim Schmoll, MD, PhD Tags: Conferences/ASCO 2017 Gastrointestinal Cancers Symposium Videos Gastrointestinal Cancers Source Type: news

Transparency around Value to Support Rational Pricing Discussions
The issue of drug pricing has become a staple of the news cycle, with fresh headlines every few weeks spotlighting either the high cost of new breakthrough drugs like Sovaldi, or jaw-dropping price hikes for existing, popular products like the EpiPen. While these examples represent two very different sets of issues, in the minds of consumers, they boil down to the same thing: drugs cost too much, and drug companies are to blame. And the only framework for a rational discussion of the subject rests on a transparent, data-based value case for the product in question.Much of the public sensitivity to drug pricing is a functio...
Source: EyeForPharma - December 28, 2016 Category: Pharmaceuticals Authors: Rita E. Numerof Ph.D. Source Type: news

Bevacizumab Approved for Another Type of Ovarian Cancer Bevacizumab Approved for Another Type of Ovarian Cancer
The latest FDA approval is for use in patients with platinum-sensitive recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.FDA Approvals (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 12, 2016 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news

Avastin (Bevacizumab) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - December 12, 2016 Category: Drugs & Pharmacology Source Type: news

Roche's Avastin (bevacizumab) plus chemotherapy receives FDA approval for platinum-sensitive recurrent ovarian cancer
Roche (SIX: RO, ROG; OTCQX: RHHBY) has announced that the U.S. Food and Drug Administration (FDA) has approved Avastin® (bevacizumab), either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine chemotherapy, followed by Avastin alone, for the treatment of patients with platinum-sensitive recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. (Source: World Pharma News)
Source: World Pharma News - December 9, 2016 Category: Pharmaceuticals Tags: Featured Roche Business and Industry Source Type: news

Roche ’s Avastin (bevacizumab) plus chemotherapy receives FDA approval for platinum-sensitive recurrent ovarian cancer
Roche today announced that the U.S. Food and Drug Administration (FDA) has approved Avastin ® (bevacizumab), either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine chemotherapy, followed by Avastin alone, for the treatment of patients with platinum-sensitive recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. (Source: Roche Media News)
Source: Roche Media News - December 7, 2016 Category: Pharmaceuticals Source Type: news

Roche ’s Avastin (bevacizumab) plus chemotherapy receives FDA approval for platinum-sensitive recurrent ovarian cancer
Roche today announced that the U.S. Food and Drug Administration (FDA) has approved Avastin ® (bevacizumab), either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine chemotherapy, followed by Avastin alone, for the treatment of patients with platinum-sensitive recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. (Source: Roche Investor Update)
Source: Roche Investor Update - December 7, 2016 Category: Pharmaceuticals Source Type: news

FDA Approves Avastin (bevacizumab) Plus Chemotherapy for a Specific Type of Advanced Ovarian Cancer
South San Francisco, CA -- December 6, 2016 -- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved Avastin (bevacizumab), either in combination with... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - December 6, 2016 Category: Drugs & Pharmacology Source Type: news

Amgen, Allergan apply for European nod for Avastin biosimilar
(Reuters) - Amgen Inc and Allergan Plc said they have submitted an application to the European health regulator seeking approval of their biosimilar version of Roche Holding AG's blockbuster cancer treatment, Avastin. (Source: Reuters: Health)
Source: Reuters: Health - December 2, 2016 Category: Consumer Health News Tags: healthNews Source Type: news

Amgen And Allergan Submit Biosimilar Marketing Authorization Application To European Medicines Agency For ABP 215, A Biosimilar Candidate To Bevacizumab
Supported by Phase 3 Study in Patients With Non-Squamous Non-Small Cell Lung Cancer THOUSAND OAKS, Calif., Dec. 2, 2016 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Allergan plc. (NYSE:AGN) today announced the submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for ABP 215, a biosimilar candidate to Avastin® (bevacizumab). The companies believe this submission is the first bevacizumab biosimilar application submitted to the EMA. "The submission of ABP 215 to the EMA is an important milestone as Amgen seeks to expand our oncology portfolio," said Sean E. Harper,...
Source: Amgen News Release - December 2, 2016 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Study Uncovers Strange Growth of Mesothelioma Tumors
A new analysis on how asbestos-related tumors grow may lead to more effective research and treatments of malignant mesothelioma. Researchers at Australia’s Flinders University found malignant mesothelioma tumors demonstrate vasculogenic (vascular) mimicry — the process in which tumors make their own blood vessels. Tumors promote their own growth by growing blood vessels that reach into surrounding tissues instead of waiting for the outside of the tissue to grow blood vessels into the cancer cells. Oxygen and nutrients from blood vessels allow cancer cells to develop into secondary tumors. “[Vasculogen...
Source: Asbestos and Mesothelioma News - November 29, 2016 Category: Environmental Health Authors: Walter Pacheco Tags: cancer tumor growth chemotherapy for mesothelioma growth of mesothelioma tumors how do mesothelioma tumors grow mesothelioma clinical trials mesothelioma research mesothelioma treatment mesothelioma tumor growth Source Type: news

Allergan, Amgen Submit BLA for Avastin Biosim
ABP 215 is the most advanced of the four oncology biosimilar medicines on which Amgen and Allergan are collaborating (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - November 16, 2016 Category: Pharmaceuticals Source Type: news

Boehringer Ingelheim bevacizumab biosimilar candidate demonstrates bioequivalence to Avastin ®
(Source: Boehringer Ingelheim Press Releases)
Source: Boehringer Ingelheim Press Releases - November 16, 2016 Category: Research Source Type: news

Amgen And Allergan Submit Biosimilar Biologics License Application For ABP 215 To U.S. Food And Drug Administration
Supported by Phase 3 Study in Patients With Non-Squamous Non-Small Cell Lung Cancer THOUSAND OAKS, Calif., Nov. 15, 2016 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Allergan plc. (NYSE:AGN) today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for ABP 215, a biosimilar candidate to Avastin® (bevacizumab). ABP 215 is the most advanced of the four oncology biosimilar medicines that Amgen and Allergan are collaborating on. The companies believe this submission is the first bevacizumab biosimilar application submitted to the FDA. "ABP 215 is one of f...
Source: Amgen News Release - November 15, 2016 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

CRLX101/Bevacizumab Combination No Better Than Standard Care in Metastatic RCC
The combination of bevacizumab and an investigational nanoparticle-drug conjugate known as CRLX101 failed to improve outcomes in metastatic renal cell carcinoma compared with standard of care. (Source: CancerNetwork)
Source: CancerNetwork - November 5, 2016 Category: Cancer & Oncology Authors: Dave Levitan Tags: Genitourinary Cancers Conferences/IKCS 2016 Kidney Cancer News Source Type: news

FDA Alerts Health Care Professionals of Infection Risk from Repackaged Avastin Intravitreal Injections
(Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - November 1, 2016 Category: Drugs & Pharmacology Source Type: news

Bevacizumab/Everolimus Active in Certain Non –Clear Cell RCC Histologies
The combination of bevacizumab and everolimus had efficacy in patients with unclassified non –clear cell renal cell carcinoma characterized by papillary features, resulting in an objective response rate of 43%. (Source: CancerNetwork)
Source: CancerNetwork - September 15, 2016 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Genitourinary Cancers Kidney Cancer News Renal Cell Carcinoma Source Type: news

‘ Botox Police ’ : FDA crime unit draws fire over import crackdown
(Reuters) – On April 5, 2012, a criminal investigator from the Food and Drug Administration named Robert West charged into an oncology clinic in Greenville, Tennessee. West was chasing a lead that Dr. Anindya Sen and his wife, the clinic’s office manager Patricia Posey Sen, purchased an unapproved Turkish version of the cancer drug Avastin. But “Cowboy Bob,” as some defense attorneys call him, did not realize his interview was caught on the clinic’s surveillance cameras. West told Posey Sen she was guilty of buying counterfeit drugs and looked like a “deer in the headlights,” court...
Source: Mass Device - September 9, 2016 Category: Medical Equipment Authors: MassDevice Tags: Cosmetic/Aesthetic Food & Drug Administration (FDA) Source Type: news

Combo Tx Promising in Non-Clear Cell Renal Carcinoma (CME/CE)
(MedPage Today) --'Compelling'results from Zortress-Avastin phase II trial (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - September 8, 2016 Category: Hematology Source Type: news

Doc's Dilemma: Lucentis or Avastin?
(MedPage Today) -- A physician weighs the risks and benefits (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - July 28, 2016 Category: American Health Source Type: news

New Mesothelioma Treatment Guidelines May Extend Survival
The National Comprehensive Cancer Network (NCCN) has changed its first-line treatment recommendation for unresectable pleural mesothelioma, believing it will extend patient survival significantly. The NCCN advisory panel recently added the monoclonal antibody bevacizumab to the long-standing chemotherapy combination of pemetrexed and cisplatin. Bevacizumab, also known by brand name Avastin, inhibits the formation of new blood vessels in tumors, effectively slowing the growth of cancer cells. It has successfully treated some types of lung and colorectal cancers. The NCCN recommendation is expected to be a precursor to the U...
Source: Asbestos and Mesothelioma News - July 26, 2016 Category: Environmental Health Authors: Walter Pacheco Tags: cancer chemotherapy chemotherapy drugs chemotherapy drugs for mesothelioma chemotherapy for mesothelioma mesothelioma treatment moffitt cancer center new chemotherapy drug Source Type: news

Chemotherapy Plus Bevacizumab Promising in Advanced TNBC
A triplet regimen including paclitaxel, capecitabine, and bevacizumab showed efficacy and safety in women with advanced triple-negative breast cancer. (Source: CancerNetwork)
Source: CancerNetwork - July 18, 2016 Category: Cancer & Oncology Authors: Dave Levitan Tags: Breast Cancer News Triple-Negative Breast Cancer Source Type: news

Amgen Teams with Daiichi Sankyo on Biosimilars Deal
U.S.-based Amgen Inc. announced an exclusive agreement with Daiichi Sankyo for the commercialization of nine biosimilars in Japan including biosimilars of AbbVie’s Humira and Roche Holding's Avastin and Herceptin. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - July 15, 2016 Category: Pharmaceuticals Source Type: news

NovoCure wins FDA nod for next-gen Optune device
NovoCure (NSDQ:NVCR) said today it won FDA premarket approval for its 2nd-generation Optune system designed to treat glioblastoma patients. The Optune is a mobile device that delivers low-intensity, intermediate frequency, alternating electric fields, referred to as “tumor treating fields” to inhibit cancer cell replication and cause cancer cell death. The next-generation device is smaller, lighter and features a tumor treating field generator that is less than half the weight and size of the 1st-generation Optune system, NovoCure said. “From the start, Novocure’s mission has been to improve th...
Source: Mass Device - July 14, 2016 Category: Medical Equipment Authors: Fink Densford Tags: 510(k) Food & Drug Administration (FDA) Oncology Regulatory/Compliance NovoCure Source Type: news

Amgen And Daiichi Sankyo Announce Agreement To Commercialize Biosimilars In Japan
THOUSAND OAKS, Calif. and TOKYO, July 13, 2016 -- (Healthcare Sales & Marketing Network) -- Amgen (AMGN) and Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo; TSE: 4568) today announced the execution of an exclusive agreement to commercialize ni... BiopharmaceuticalsAmgen, Daiichi Sankyo, biosimilars, adalimumab, bevacizumab, trastuzumab (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - July 14, 2016 Category: Pharmaceuticals Source Type: news

Amgen and Daiichi Sankyo announce agreement to commercialize biosimilars in Japan
Amgen (NASDAQ:AMGN) and Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo; TSE 4568) today announced the execution of an exclusive agreement to commercialize nine biosimilars in Japan. The deal includes several biosimilars in late stage development, including biosimilars of adalimumab, bevacizumab and trastuzumab. (Source: World Pharma News)
Source: World Pharma News - July 14, 2016 Category: Pharmaceuticals Tags: Featured Daiichi Sankyo Business and Industry Source Type: news

Amgen And Daiichi Sankyo Announce Agreement To Commercialize Biosimilars In Japan
Exclusive Agreement Includes Nine Biosimilars THOUSAND OAKS, Calif. and TOKYO, July 13, 2016 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo; TSE: 4568) today announced the execution of an exclusive agreement to commercialize nine biosimilars in Japan. The deal includes several biosimilars in late-stage development, including biosimilars of adalimumab, bevacizumab and trastuzumab. Under the terms of the agreement, Amgen will remain responsible for the development and manufacturing of the biosimilars. Daiichi Sankyo will file for marketing approval and be respo...
Source: Amgen News Release - July 14, 2016 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Low LDH May Predict Second-Line Bevacizumab CRC ResponseLow LDH May Predict Second-Line Bevacizumab CRC Response
The addition of bevacizumab to second-line chemotherapy in metastatic colorectal cancer could be targeted to patients with low lactate dehydrogenase (LDH) levels, say Italian scientists. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 7, 2016 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Eye drug safety: the impact of a Cochrane Review comparing two treatments for macular degeneration
For more than 20 years, Cochrane has produced systematic reviews of primary research in human health care and health policy. We are internationally recognized as the highest standard in evidence-based healthcare resources.The fourth video in the Cochrane Making a Difference series focuses on the Cochrane Review 'Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration', published in September 2014 from the Cochrane Eyes & Vision Group. The review found that the systemic safety of bevacizumab for macular degeneration appears to be similar to that of ranibizumab - an important co...
Source: Cochrane News and Events - July 1, 2016 Category: Information Technology Authors: nowens at cochrane.org Source Type: news

Oncolytics begins Phase II trial of Reolysin in female patients with colorectal cancer
Canadian-based biotechnology company Oncolytics has initiated the Phase II trial of Reolysin (pelareorep) in combination with FOLFOX6, bevacizumab and pembrolizumab in female patients with KRAS-mutant colorectal cancer (CRC) metastatic to the liver. (Source: Drug Development Technology)
Source: Drug Development Technology - July 1, 2016 Category: Pharmaceuticals Source Type: news

Routine use of bevacizumab for cervical cancer not sustainable
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - July 1, 2016 Category: Drugs & Pharmacology Source Type: news

Russia Drug Maker Accuses Roche of Sabotaging Biosimilars
According to Biocad, Roche dropped prices on cancer medicines — Avastin, Herceptin, and Rituxan/MabThera — in Russia, where Biocad sells biosimilar versions of the three drugs. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - June 23, 2016 Category: Pharmaceuticals Source Type: news

Best diabetic macular oedema drugs ‘not cost-effective’
Resource utilisation data from the Diabetic Retinopathy Clinical Research Network Comparative Effectiveness Trial show that the most efficacious drug for diabetic macular oedema, aflibercept, is not cost-effective relative to repackaged bevacizumab. (Source: MedWire News)
Source: MedWire News - June 17, 2016 Category: Consumer Health News Tags: Diabetes Source Type: news

Two Expensive Diabetic Macular Edema Drugs Not Cost-effectiveTwo Expensive Diabetic Macular Edema Drugs Not Cost-effective
Anti-VEGF medicines aflibercept and ranibizumab would have to drop in price by 69% and 80%, respectively, to be worth the societal cost compared with bevacizumab, a new study has found. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 9, 2016 Category: Consumer Health News Tags: Ophthalmology News Source Type: news